Rhelion Life Sciences Corp.
TRUFF
$0.02
$0.008.42%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -15.25% | -23.86% | -27.81% | -10.56% | 1.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.25% | -23.86% | -27.81% | -10.56% | 1.29% |
| Cost of Revenue | -14.15% | -18.61% | -23.59% | -3.68% | 7.99% |
| Gross Profit | -16.96% | -32.05% | -34.00% | -20.24% | -7.76% |
| SG&A Expenses | -4.03% | -19.76% | -27.06% | -27.29% | -25.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 100.00% | 100.00% | -- | -- |
| Total Operating Expenses | -5.72% | -18.22% | -25.08% | -22.34% | -18.71% |
| Operating Income | -5.50% | 12.03% | 22.20% | 32.97% | 34.06% |
| Income Before Tax | -63.65% | 16.59% | 28.77% | 42.75% | 45.26% |
| Income Tax Expenses | -211.84% | -581.77% | -378.46% | -217.88% | -71.30% |
| Earnings from Continuing Operations | -60.05% | 18.95% | 30.84% | 44.25% | 46.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 184.71% | 102.03% | 156.29% | 117.35% | 192.37% |
| Net Income | -51.96% | 21.20% | 33.58% | 46.85% | 48.86% |
| EBIT | -5.50% | 12.03% | 22.20% | 32.97% | 34.06% |
| EBITDA | -44.84% | 2.07% | 18.32% | 33.99% | 37.16% |
| EPS Basic | -47.22% | 23.01% | 35.00% | 48.46% | 49.65% |
| Normalized Basic EPS | 10.81% | 18.37% | 31.48% | 45.00% | 44.78% |
| EPS Diluted | -158.33% | 23.01% | 35.00% | 48.46% | 49.65% |
| Normalized Diluted EPS | 10.81% | 18.37% | 31.48% | 45.00% | 44.78% |
| Average Basic Shares Outstanding | 3.86% | 3.17% | 2.54% | 2.05% | 1.49% |
| Average Diluted Shares Outstanding | 3.86% | 3.17% | 2.54% | 2.05% | 1.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |